Science & Research — Page 3

Transcranial magnetic stimulation is the only FDA-cleared neuromodulation technology for addiction treatment. This evidence review explains how TMS works, what conditions have the most evidence, and how it fits into comprehensive addiction care programs.

Relapse is a common feature of substance use disorders, yet it is neither inevitable nor beyond scientific understanding. Research has identified specific neurobiological mechanisms, environmental triggers, and psychological vulnerabilities that predict relapse risk, and has validated multiple effective prevention strategies. Understanding this science empowers individuals and treatment providers to dramatically reduce relapse rates.

Research consistently shows that genetics account for 40 to 60 percent of addiction vulnerability. This article examines the specific genes, neurobiological pathways, and heritability data that shape individual risk profiles.

How do we know if addiction treatment works? Treatment outcome studies answer this critical question by systematically measuring changes in substance use, health, functioning, and quality of life following treatment. This review examines landmark outcome studies, key measurement approaches, and what the evidence reveals about factors most strongly associated with long-term recovery.

Neuroplasticity — the brain's lifelong capacity to rewire itself through experience — is the biological foundation of recovery from addiction. New research reveals how the addicted brain heals, which interventions accelerate this process, and why recovery truly gets easier over time.

MDMA-assisted therapy showed extraordinary promise in Phase 3 trials for PTSD before a landmark 2024 FDA rejection. This review explains the science, the setback, and why this approach remains among the most important ongoing areas of research for treating trauma-driven addiction.

Clinical trials are the gold standard for establishing the safety and effectiveness of addiction treatments. This review examines landmark recent trials reshaping clinical practice, from extended-release naltrexone for opioid use disorder to digital therapeutics and emerging pharmacological targets for stimulant use disorders.

Randomized controlled trials of psilocybin-assisted therapy for alcohol and tobacco addiction have produced some of the most remarkable effect sizes seen in addiction medicine research. This detailed review examines what these trials actually found, their methodological strengths and limitations, and what they mean for future treatment.

Endorphins are the brain's natural opioids, released in response to pain, exercise, and social bonding to promote survival and wellbeing. Understanding how opioid drugs mimic and ultimately suppress this system reveals why opioid use disorder is both biologically powerful and clinically treatable.

Neuroimaging technologies have given scientists unprecedented windows into the living addicted brain, transforming addiction from an abstract behavioral concept into a visible, measurable neurological condition. This review examines what fMRI, PET scans, and diffusion tensor imaging reveal about the brain changes underlying addiction and how these findings inform treatment.

Serotonin influences mood, impulse control, appetite, sleep, and social behavior — making it central to both mental health and addiction. When substance use disrupts serotonin signaling, the consequences extend far beyond simple mood changes. Trust SoCal explains the neuroscience and its clinical implications.

Ketamine clinics have proliferated across Southern California, marketed for depression, PTSD, and increasingly for addiction. This evidence review separates established science from commercial overreach, helping patients and families make informed decisions.

SAMHSA's annual National Survey on Drug Use and Health provides the most comprehensive picture of substance use and mental health in America. This analysis examines NSDUH data on prevalence rates, treatment access, demographic disparities, and emerging trends that inform clinical priorities for addiction treatment providers.

Gamma-aminobutyric acid (GABA) is the brain's primary inhibitory neurotransmitter, governing everything from anxiety levels to sleep quality. When substances like alcohol and benzodiazepines hijack the GABA system, the consequences of withdrawal can be medically severe. Trust SoCal explains the science and the safe path forward.

The National Institute on Drug Abuse has produced decades of research establishing the scientific foundation for addiction treatment. This summary examines key NIDA findings on what works, what does not, and how evidence-based care transforms outcomes for individuals with substance use disorders.

Psychedelic therapy research is undergoing a renaissance, with rigorous clinical trials demonstrating that compounds like psilocybin and MDMA may offer breakthrough treatment for addiction. Learn what the science actually shows and how these findings may shape future care.

The dopamine reward pathway is the brain's most powerful motivational circuit — and the primary target of every addictive substance. Discover how this system works, how drugs exploit it, and what recovery looks like from a neurobiological perspective.